Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.

Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY.

Oncogene. 2011 Feb 17;30(7):770-80. doi: 10.1038/onc.2010.458. Epub 2010 Oct 11.

2.

Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.

Zhang X, Ding L, Kang L, Wang ZY.

PLoS One. 2012;7(1):e30174. doi: 10.1371/journal.pone.0030174. Epub 2012 Jan 19.

3.

Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.

Zhang XT, Ding L, Kang LG, Wang ZY.

Oncol Rep. 2012 Jun;27(6):2057-65. doi: 10.3892/or.2012.1722. Epub 2012 Mar 15.

4.

Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.

Zhang X, Deng H, Wang ZY.

J Steroid Biochem Mol Biol. 2014 Sep;143:434-43. doi: 10.1016/j.jsbmb.2014.06.009. Epub 2014 Jun 25.

PMID:
24973581
5.

Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.

Wang X, Zheng N, Dong J, Wang X, Liu L, Huang J.

J Steroid Biochem Mol Biol. 2017 Jul;171:318-327. doi: 10.1016/j.jsbmb.2017.05.009. Epub 2017 May 18.

PMID:
28529129
6.

A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.

Kang L, Guo Y, Zhang X, Meng J, Wang ZY.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):262-8. doi: 10.1016/j.jsbmb.2011.08.011. Epub 2011 Sep 3.

7.

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Lin SL, Yan LY, Zhang XT, Yuan J, Li M, Qiao J, Wang ZY, Sun QY.

PLoS One. 2010 Feb 2;5(2):e9013. doi: 10.1371/journal.pone.0009013.

8.

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Li G, Zhang J, Jin K, He K, Zheng Y, Xu X, Wang H, Wang H, Li Z, Yu X, Teng X, Cao J, Teng L.

Mol Oncol. 2013 Jun;7(3):611-24. doi: 10.1016/j.molonc.2013.02.001. Epub 2013 Feb 26.

9.

ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.

Deng H, Zhang XT, Wang ML, Zheng HY, Liu LJ, Wang ZY.

PLoS One. 2014 Feb 18;9(2):e88034. doi: 10.1371/journal.pone.0088034. eCollection 2014.

10.

Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.

Zhang X, Wang ZY.

Endocrinology. 2013 Jun;154(6):1990-8. doi: 10.1210/en.2013-1116. Epub 2013 Apr 1.

PMID:
23546601
11.

Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.

Wang ZY, Yin L.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:193-206. doi: 10.1016/j.mce.2015.04.017. Epub 2015 Apr 24. Review.

PMID:
25917453
12.

A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells.

Guo M, Wang M, Deng H, Zhang X, Wang ZY.

Eur J Pharmacol. 2013 Aug 15;714(1-3):56-64. doi: 10.1016/j.ejphar.2013.05.047. Epub 2013 Jun 11.

PMID:
23769740
13.

Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.

Pan C, Hu Y, Li J, Wang Z, Huang J, Zhang S, Ding L.

PLoS One. 2014 Aug 15;9(8):e104459. doi: 10.1371/journal.pone.0104459. eCollection 2014.

14.

ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.

Tong JS, Zhang QH, Wang ZB, Li S, Yang CR, Fu XQ, Hou Y, Wang ZY, Sheng J, Sun QY.

PLoS One. 2010 Nov 4;5(11):e15408. doi: 10.1371/journal.pone.0015408.

15.

Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.

Shi YE, Chen Y, Dackour R, Potters L, Wang S, Ding Q, Wang Z, Liu YE.

Am J Pathol. 2010 Aug;177(2):964-73. doi: 10.2353/ajpath.2010.100061. Epub 2010 Jul 1.

16.
17.

ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer.

Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY, Qiao J.

Am J Obstet Gynecol. 2011 Sep;205(3):227.e1-6. doi: 10.1016/j.ajog.2011.04.015. Epub 2011 Apr 16.

PMID:
21684519
18.
19.

Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.

Pan X, Zhao B, Song Z, Han S, Wang M.

J Pharmacol Sci. 2016 Feb;130(2):85-93. doi: 10.1016/j.jphs.2015.12.003. Epub 2015 Dec 15.

20.

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY.

PLoS One. 2014 Sep 9;9(9):e107369. doi: 10.1371/journal.pone.0107369. eCollection 2014.

Supplemental Content

Support Center